

Drug Utilization Review (DUR) Meeting Minutes September 13, 2010

Members Present: Norman Byers, Carrie Sorenson, Jeffrey Hostetter, John Savageau, Carlotta McCleary, David Clinkenbeard, Russ Sobotta, Cheryl Huber, Kim Krohn, Greg Pfister, Patricia Churchill

Members Absent: James Carlson, Steve Irsfeld, Leann Ness, Todd Twogood

Medicaid Pharmacy Department: Brendan Joyce, Gary Betting

HID Staff Present: Candace Rieth

Chair, J. Hostetter called the meeting to order at 1:04 pm. Chair, J. Hostetter asked for a motion to approve the minutes from the June meeting. N. Byers moved that the minutes be approved and P. Churchill seconded the motion. Chair, J. Hostetter called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Budget Update

Enrollment is estimated to be approximately 62,300. This number does not include any changes in enrollment due to Health Care Reform. Although spend has not seen a drastic increase, the cost per member per month is gradually increasing. Post rebate dollars remain steady, although the rebate process as a whole is changing with an ultimate shift in dollars back to the federal government. The outcome of this shift is unknown at this time.

Intuniv Second Review

A motion and second were made at the June meeting to place Intuniv on prior authorization. The topic was brought up for a second review. B. Joyce reminded the Board that legislative intent would be researched by the Department's legal staff prior to any implementation of prior authorization on this drug. There was no public comment. After discussion, Chair, J. Hostetter called for a voice vote to approve the motion. The motion passed with two audible dissents.

Xolair Second Review

A motion and second were made at the June meeting to place Xolair on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair, J. Hostetter called for a voice vote to approve the motion. The motion passed with no audible dissent.

Ampyra Second Review

A motion and second were made at the June meeting to place Ampyra on prior authorization. The topic was brought up for a second review. There was no public comment. A motion was made by P. Churchill to amend the original motion and require that patients using Ampyra be evaluated by a neurologist or psychiatrist. C. Sorenson seconded the motion. Chair, J. Hostetter called for a voice vote to approve the amended motion. The motion passed with no audible dissent.

Ribapak Second Review

A motion and second were made at the June meeting to place Ribapak on prior authorization. The topic was brought up for a second review. There was no public comment. Chair, J. Hostetter called for a voice vote to approve the motion. The motion passed with no audible dissent.

Emla Second Review

A motion and second were made at the June meeting to place Emla on prior authorization. The topic was brought up for a second review. There was no public comment. N. Byers made a motion to amend the original motion to change the form name to Topical Anesthetic Agents and to include a criterion that prior authorization is not required for patients 12 years of age and

younger. J. Savageau seconded the motion. Chair, J. Hostetter called for a voice vote to approve the amended motion. The motion passed with no audible dissent.

Narcotic Second Review

A motion and second were made at the June meeting to place brand-name narcotics and tramadol ER on prior authorization. The topic was brought up for a second review. There was no public comment. C. Huber made a motion to amend the original motion to exclude the dose equivalent portion of the name-brand narcotic criterion. P. Churchill seconded the motion. Chair, J. Hostetter called for a voice vote to approve the amended motion. The motion passed with no audible dissent.

Metozolv Second Review

A motion and second were made at the June meeting to place Metozolv on prior authorization. The topic was brought up for a second review. There was no public comment. Chair, J. Hostetter called for a voice vote to approve the motion. The motion passed with no audible dissent.

Yearly PA Review

The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. Dispense as written, Amrix/Fexmid, Xenical, Zanaflex capsules, Ketek, and Aczone forms and criteria were reviewed. For clarification, a Medwatch form is required when a PA request states that a recipient failed a generic due to adverse reactions. No other changes were made to the forms or criteria that were reviewed.

Interferon Review

B. Joyce reviewed Interferon utilization with the Board. There was no public comment. After discussion, N. Byers made a motion to place interferons on prior authorization. G. Pfister seconded the motion. This topic will be brought up at the next meeting for finalization.

Orally-disintegrating dosage form Review

B. Joyce reviewed a list of products that are available in an orally-disintegrating dosage form. There was no public comment. B. Joyce noted that orally-disintegrating dosage forms in the six exempt drug classes (Antipsychotics, Antidepressants, Anticonvulsants, stimulants used to treat ADHD, HIV/AIDS meds and Oncology meds) will be excluded from this prior authorization. After discussion, K. Krohn made a motion to place orally-disintegrating products on prior authorization that cost more than the original product. D. Clinkenbeard seconded the motion. This topic will be brought up at the next meeting for finalization.

Oravig Review

B. Joyce reviewed Oravig information with the Board. There was no public comment. After discussion, J. Savageau made a motion to place Oravig on prior authorization. C. Sorenson seconded the motion. This topic will be brought up at the next meeting for finalization.

Zyclara Review

B. Joyce reviewed Zyclara information with the Board. There was no public comment. After discussion, N. Byers made a motion to place Zyclara on prior authorization. C. Huber seconded the motion. This topic will be brought up at the next meeting for finalization.

Clorpres Review

B. Joyce reviewed Clorpres information with the Board. There was no public comment. After discussion, P. Churchill made a motion to place Clorpres on prior authorization. K. Krohn seconded the motion. This topic will be brought up at the next meeting for finalization.

Livalo Review

B. Joyce reviewed Livalo information with the Board. There was no public comment. After discussion, G. Pfister made a motion to place Livalo on prior authorization. N. Byers seconded the motion. This topic will be brought up at the next meeting for finalization.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. K. Krohn moved to approve the new criteria and N. Byers seconded the motion. Chair, J. Hostetter called for a voice vote. The motion passed with no audible dissent.

Election of Chair and Vice-Chair

C. Huber made a motion that G. Pfister be considered as the new Chair of the DUR Board and T. Twogood be considered as the new Vice-Chair. K. Krohn seconded the motion. Chair, J. Hostetter called for a voice vote with no audible dissent. G. Pfister and T. Twogood will serve as the new Chair and Vice-Chair, respectively.

The next DUR board meeting will be held December 6, 2010. C. Sorenson made a motion to adjourn the meeting. G. Pfister seconded. The motion passed with no audible dissent. Chair J. Hostetter adjourned the meeting at 2:40 pm.